Clinigene International and SCIREX Corporation to Collaborate on Global Clinical Trials
Clinigene International, a wholly owned subsidiary of India's premier Biotech enterprise, Biocon Limited, and SCIREX Corporation, a wholly owned subsidiary of the Omnicom Group, have announced that they have signed a Letter of Intent (LOI) to collaborate on global clinical trials.
(PRWEB) June 30, 2005 -- Clinigene International, a wholly owned subsidiary
of India's premier Biotech enterprise, Biocon Limited, and SCIREX Corporation, a
wholly owned subsidiary of the Omnicom Group, have announced that they have
signed a Letter of Intent (LOI) to collaborate on global clinical trials. The
LOI was signed at SCIREX’s Headquarters in Horsham, Pennsylvania, USA, during a
recent visit by Dr. Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon
and Dr. Arvind Atignal, Chief Operating Officer, Clinigene.
With India
rapidly emerging as a key locale for clinical research, the new relationship
provides SCIREX clients immediate access to well developed expertise in clinical
investigation in India and provides Clinigene the opportunity to expand its
markets and partake in global clinical trial programs.
"SCIREX is
extremely pleased to forge a new kind of exclusive partnership in India. “We
were a natural fit from the very beginning,” said SCIREX CEO Jim Utterback.
“This brings our clients a best in class firm that not only offers them
substantial value based on cost efficiencies and great science but also
demonstrated clinical trial expertise. SCIREX and our parent, Omnicom Group, can
be truly integrated research and commercialization partners with Clinigene for
years to come."
Dr. Mazumdar-Shaw said that she saw the partnership as a
natural evolution for Clinigene and Biocon given the “significant investment
made over the past decade in systems, processes, and people. We are proud of the
leading role we have taken in India and look forward to enabling SCIREX’s
clients to benefit from the quality and speed of clinical development in
India.”
“SCIREX’s expertise and vast experience in IND Filings and
conduct of Global Clinical Trials will further position Biocon/Clinigene as a
world-class clinical development organization,” added Dr. Arvind Atignal.
“At the end of the day, the CRO business is about expertise, leadership
and commitment to creating value. I feel our respective companies’ personalities
and cultures were a perfect fit," said Utterback.
About SCIREX
SCIREX
Corporation (www.scirex.com)
is an industry leader in the delivery of Phase I-IV drug development services to
the global pharmaceutical and biotechnology industry. SCIREX possesses
capabilities in clinical trial management, drug development planning, protocol
design, submission services, regulatory affairs consulting, investigator and
patient recruitment, data management, statistics, medical writing and offers an
array of technology solutions. SCIREX has experience from more than 1,000
clinical trials involving well over 130,000 patients, in pain and inflammation,
neurological and psychiatric disorders, infectious diseases and gastrointestinal
and cardiovascular indications. SCIREX is a wholly-owned subsidiary of Omnicom
Group, Inc. (NYSE: OMC) (www.omnicomgroup.com). Omnicom is a leading global
advertising, marketing and corporate communications company.
About
Clinigene
Established in 2000, Clinigene is one of India’s leading Clinical
Research Organisations that offers comprehensive clinical services from Phase 1
- Phase 4. The company maintains disease-focused patient registries and clinical
databases in diabetes, lipidemia, oncology and cardiovascular diseases that
enable faster study start-up and more efficient data collection due to depth and
longevity of their site and investigator relationships. Clinigene’s Clinical
Research Facilities are accredited by the CAP - College of American
Pathologists, USA. Currently Clinigene is carrying out a Phase IIB study for
Biocon Biopharmaceutical’s Monoclonal Antibody targeted against Head and Neck
Cancer and is in the process of filing an IND for Biocon’s Oral
Insulin.
About Biocon Group
Established in 1978, Biocon is India's
premier biotechnology company with consolidated revenues in excess of USD 150
Million and a Market Capitalisation of about USD 1 Billion. Biocon and its three
subsidiary companies, Syngene International Private Limited, Clinigene
International Private Limited and Biocon Biopharmaceuticals Private Limited,
form a fully integrated biotechnology enterprise specializing in
biopharmaceuticals, custom research, clinical research and enzymes. With
successful initiatives in drug discovery, clinical development, bioprocessing
and global marketing, Biocon delivers products and solutions to partners and
customers across 70 countries. (www.biocon.com).
# # #
Source : http://www.prweb.com/releases/2005/6/prweb256255.htm